ELIGARD 7.5 MG

What is ELIGARD?

ELIGARD 7.5 MG contains LEUPROLIDE ACETATE : 7.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02248239, held by TOLMAR INTERNATIONAL LTD., supplied as POWDER FOR SUSPENSION, SUSTAINED-RELEASE for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 30-May-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is ELIGARD used for?

ELIGARD 7.5 mg (1 - month), 22.5 mg (3 - month), 30 mg (4 - month) and 45 mg (6 - month) are indicated for the treatment of advanced prostate cancer. ELIGARD 45 mg (6 - month) is indicated for the treatment of children 2 years of age and older with central precocious puberty (CPP).

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

How is it administered?

Administered subcutaneously by a healthcare professional. Prostate cancer: 7.5mg (1-mo), 22.5mg (3-mo), 30mg (4-mo), or 45mg (6-mo). CPP: 45mg every 6 months. Requires specific 60-cycle mixing procedure.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Note , before reconstitution, ELIGARD can be stored at room temperature (15 – 30°C) in original packaging for a period of 8 weeks prior to administration (see 11 STORAGE , STABILITY AND DISPOSAL ) .

How is it supplied?

ELIGARD 7.5, 22.5, 30 and 45 mg is packaged in one thermoformed tray placed into a paperboard carton. The ELIGARD carton contains: • Tray containing pre - connected syringe system (syringe A is pre filled with the ATRIGEL ® Delivery System and syringe B is filled with leuprolide acetate powder) and desiccant pack . • P ackage insert. • One 20 - gauge 5/8 inch sterile safety needle and cap (7.5, 22.5 and 30 mg) or one 18 - gauge 5/8 inch sterile safety needle and cap (45 mg) , provided under tray .

Contraindications

Hypersensitivity to leuprolide acetate, LH-RH, or LH-RH analogs. Females who are or may become pregnant. Nursing females.

Warnings and precautions

Serious: Testosterone flare, pituitary apoplexy, osteoporosis. Others: Convulsions, idiopathic intracranial hypertension, decreased bone density, and hypersensitivity/anaphylaxis.

What can be used instead?

Other Canadian products sharing ATC code L02AE02 LEUPRORELIN. 11 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

Who else supplies LEUPRORELIN worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. LEUPRORELIN appears in 76 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.